Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Trial Identifier:	D0817R00011
Sponsor:	AstraZeneca
NCTID::	NCT04560452
Start Date:	March 2021
Primary Completion Date:	December 2025
Study Completion Date:	December 2025
Condition:	Ovarian Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China
China, Shanghai	Shanghai, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company